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Abstract
Pathogen persistence in immune-competent hosts represents an immunological paradox. Increasing evidence
suggests that some pathogens, such as, Leishmania major (L. major) have evolved strategies and mechanisms that
actively suppress host adaptive immunity. If this notion is correct conventional vaccination therapies may be
ineffective in enhancing host immunity, unless natural processes that suppress host immunity are also targeted
therapeutically. The key problem is that the basis of pathogen persistence in immune-competent individuals is
unknown, despite decades of intense research. This fact, coupled with poor health care and a dearth of effective
treatments means that these diseases will remain a scourge on humans unless a better understanding of why the
immune system tolerates such infections emerges from research. Indoleamine 2,3-dioxygenase (IDO) has been
shown to act as a molecular switch regulating host responses, and IDO inhibitor drugs shown to possess potential
in enhancing host immunity to established leishmania infections. It is hoped that this review will help stimulate
and help generate critical new knowledge pertaining to the IDO mechanism and how to exploit it to suppress T
cell mediated immunity, thus offer an innovative approach to studying the basis of chronic leishmania infection in
mice.
Keywords: Leishimania major, Indoleamine 2,3-dioxygenase, Mice, Leishmaniasis, Host Immunity, 1-methyl-d-tryp-
tophan, plasmacytoid dendritic cell, regulatory T cell, draining lymph node
Introduction
Chronic microbial infections, such as tuberculosis,
AIDS, malaria and leishmaniasis, are a global health pro-
blem due to poor preventative health care in many
developing countries, and lack of effective vaccines and
drugs to prevent or clear chronic infections. Chronic
infections pose an immunological paradox because
pathogens persist in immune-competent hosts that, in
principle, ought to mount effective immune responses
leading to pathogen clearance. The fact that chronic
infections persist under such circumstances suggests
that pathogens exploit host immuno-regulatory mechan-
isms to protect themselves (and infected cells) by
evading or actively suppressing host immunity. This per-
spective provides the rationale for identifying natural
(host) immune-regulatory mechanisms exploited by
pathogens and using this new knowledge to improve
therapy.
This review summarizes new insights that are emer-
ging from recent studies, focusing on why Leishmania
persistence is achieved, and the other on DC subsets.
These may well be inter-connected. It is a well-known
fact that persistence is a hall mark of many parasitic
infections. In this review, we attempt to uncover a novel
mechanism by which Leishmania parasites circumvent
effector T cell responses through the induction of indo-
leamine 2,3-dioxygenase (IDO) expression. Dendritic
cell subsets (DC) are central in regulating immunity,
often establishing immunologically privileged tissue
micro environments through the induction of of T regu-
latory cells. One key concept is that only certain subsets
of DCs seem competent to express IDO, at least at the
level of functional immunoregulation. The factors that
influence the development and tissue distribution of
these IDO-competent DCs have yet to be determined.
Unanswered issues include whether the different IDO-
competent subsets arise from one or multiple lineages;
and which signals during differentiation determine their
ability to express IDO. One key mechanism that
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of the immunomodulatory enzyme IDO. For pathogens
that cause chronic infection, for example leishmania,
exploitation of DC and/or regulation of IDO presents a
simple solution to persisting within a host. These two
focuses are described later on in the text.
Leishmania major is an obligate intracellular and uni-
cellular kinetoplastid protozoan flagellate that establishes
itself within the phagolysosome of host immune compe-
tent cells, especially macrophages and dendritic cells
(DCs). In 1903, W.B. Leishman and C. Donovan
reported this new parasite at the turn of the century
[1,2]. Ronald Ross christened the new genus Leishmania
and the new species donovani in year 1903 [3]. L. major
infection (Leishmaniasis) in mice is a widely used model
of human infection that has yielded critical insights into
the immunobiology of leishmaniasis [4-6]. Leishmaniasis
as a parasitic disease manifests itself mainly in 3 clinical
forms; visceral leishmaniasis (VL), cutaneous leishmania-
sis (CL) and mucocutaneous leishmaniasis (MCL), of
which VL is the most severe form of the disease. VL is
lethal if untreated and spontaneous cure is extremely
rare. Cutaneous leishmaniasis usually has milder course
and often results into a self-healing of ulcers. Resolution
of leishmanial infection is dependent on the coordinated
interactions between components of cell mediated
immune response, specifically the activation of targeted
T-cell populations for appropriate cytokine production
and activation of macrophages. L. major infection of B6
and BALB/c mouse strains drives predominantly TH1
and TH2 responses, respectively [7-10]. In murine
model, the development of Thl response is associated
with control of infection, and Th2 response is associated
with disease progression. However, Th1 and Th2 dichot-
omy in the human system is not as distinct as in mice
and the murine model does not strictly apply to human
leishmaniasis.
Although TH1 responses are more effective than TH2
in controlling L. major infections, parasites are not
eliminated completely by B6 or BALB/c hosts [11-13].
Thus L. major parasites persist in immunocompetent
hosts, and mechanisms that explain L. major persistence
are poorly defined hitherto. Suffia and colleagues
demonstrated that Foxp3
+ regulatory T cells (Tregs) at
L. major infection sites were parasite specific [14-16].
Tregs proliferated in response to L. major infected DCs
and were restricted to sites of infection, and Treg survi-
val depended on parasite persistence. These findings
suggest that L. major parasites actively subvert host
immune responses to suppress parasite-specific effector
T cell responses. Unfortunately, counter-regulation
induced in other settings of chronic inflammation pro-
motes disease. Counter-regulation prevents excessive T
cell immunity to innocuous substances encountered
constitutively at mucosal surfaces during normal tissue
functions. Chronic inflammation associated with other
chronic infections and induced by some persistent
pathogen infections is notoriously resistant to natural as
well as vaccine-induced immunity. Resistance to T cell
immunity is a significant barrier to successful immu-
notherapy to treat chronic infections such as HIV1,
tuberculosis, and malaria. Moreover, most therapeutic
vaccines (administered to patients with pre-existing con-
ditions) have little effect on slowing disease progression,
let alone stimulating pathogen clearance. Thus, local
counter-regulatory processes that protect sites of infec-
tion are hurdles to effective immunotherapy. The well-
established paradigm that mature DCs generated at sites
of inflammation are T cell stimulatory is not consistent
with these observations. A key question is whether
mature DCs present antigens in a T cell stimulatory or
T cell regulatory fashion in inflammatory settings where
counter-regulation is predominant. Recent studies have
shown that, indoleamine 2,3-dioxygenase (IDO) has
drawn considerable attention as viable mechanism of
immune regulation [17-20]. Other known mechanisms
of immune regulation for Leishmania parasites are sum-
marized in additional file 1 [reviewed in [21]]. Studies
have demonstrated that IDO is an enzyme involved in
the catabolism of the essential amino acid tryptophan,
and the ratio of kynurenine, the main metabolite of
tryptophan, to tryptophan (kyn/trp) can be used to
reflect IDO activity. IDO is expressed mainly in antigen-
presenting cells (APCs), i.e. at the initiation of the
immune response. Its activation leads to a decrease in
the tryptophan concentration in local microenviron-
ments, thus suppressing the activation of surrounding T
lymphocytes (’suppression by starvation’)[ 1 8 ] .I na
recent study [22] we reported that chronic infection of
mice with the parasitic pathogen Leishmania major (L.
major) induces localized T cell suppression due to
induced expression of the enzyme indoleamine 2,3 diox-
ygenase (IDO). A key finding of our recent study [22]
was that IDO inhibitor treatment reduced parasite bur-
dens when administered to mice with established L.
major infections, revealing a constitutive requirement
for IDO to maintain local conditions that favor parasite
persistence and pathogenesis and suggesting that 1-
methyl-[D]-tryptophan (D-1MT) treatment may help
reduce parasite burdens in patients with leishmaniasis.
Our findings will provide new mechanistic insights into
the role of IDO-expressing cells in creating immune pri-
vilege that blocks host anti-parasite immunity. This
review focuses on the dichotomy of immune response
against L. major infection and the basis of why pathogen
persistence in immune-competent individuals is
unknown, despite decades of intense research. A com-
prehensive understanding of sequences involved in the
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ing prophylactic and therapeutic strategies against leish-
maniasis and related infections.
IDO: a natural T cell regulatory mechanism
Many study groups have shown that IDO is a conserved
intracellular enzyme that degrades compounds contain-
ing indole rings, including the essential amino acid tryp-
tophan [23-25]. In 1998, Mellor and Munn pioneered
the discovery that IDO protected fetal allografts from
potentially lethal maternal T cell immunity as shown by
the fact that the IDO-specific inhibitor D-1MT induced
fetal rejection when administered to pregnant mice [26].
The discovery of IDO as a modulator for the mainte-
nance of fetomaternal immuno-privileged state has been
heralded as a significant step in further defining the role
of IDO in immunobiology. IDO is an IFN-inducible,
intracellular enzyme that catalyzes the initial and rate-
limiting step in the degradation of the essential amino
acid, tryptophan. It has been suggested that IDO has the
capacity to regulate the immune system via two discrete
mechanisms; firstly the deprivation of tryptophan, which
is essential for T cell proliferation and via the cytotoxic
effects of tryptophan metabolites on TH1 cell survival.
As we currently do not fully understand the remarkable
immunosuppressive potency that is mediated by small
numbers of IDO
+ DCs, it is probably wise to consider
all potential mechanisms that might amplify the direct
regulatory effects of IDO. Hypothetically, mechanisms
by which suppression of adjacent T cells might occur
are not limited to bystander suppression mediated by
the IDO-expressing DC itself alone, because this may
occur either through toxic metabolites, widespread local
tryptophan depletion or IDO-induced regulatory cyto-
kines. Macrophages, regulatory T or B cells might simi-
larly be induced by IDO-responsive signalling pathways
to secrete regulatory cytokines. Naive T cells (CD4
+ or
CD8
+) might be biased by IDO
+ DCs to adopt a regula-
tory phenotype. Any of these effects could then suppress
nearby T cells responding to IDO
- antigen-presenting
cells (APCs). The effect of IDO would therefore be to
convert the local tissue microenvironment into a toleriz-
ing milieu, even for antigens presented by other, nor-
mally immunogenic APCs. Additionally, this may
involve a self-amplifying regulatory network involving
interactions between IDO-competent DCs and regula-
tory T cells. The generation of regulatory T cells by
IDO-expressing DCs could be a potent mechanism, as
these regulatory T cells might in turn create other tol-
erogenic DCs through the induction of IDO expression
by cytotoxic T lymphocyte antigen 4 (CTLA4) interac-
tions. This could provide one possible molecular
mechanism for epitope spreading and ‘infectious’ toler-
ance, as described in other systems [Reviewed in [27]].
Subsequent studies have shown that IDO activity regu-
lates T cell responses in a range of inflammatory disease
syndromes of clinical significance, including tumor
growth and infectious, autoimmune & allergic diseases
[27]. Thus, D-1MT treatment enhanced tumor-specific
or pathogen (HIV)-specific T cell immunity in tumor
and HIV-infection models [28-31]. Conversely, adminis-
tering D-1MT to mice with experimental autoimmune
and allergic disease syndromes increased disease severity
and tissue pathology, and in some cases decreased survi-
val. In addition several studies have shown that IDO
inducers, genetically enhanced expression of IDO, or
adoptive transfer of DCs induced to express IDO pro-
tects transplanted allogeneic tissues from attack by host
T cells. These observations show that IDO is a natural
immune-regulatory mechanism, which may be exploited
by disease promoting agents, such as tumors and infec-
tious pathogens, implying that the IDO mechanism may
be manipulated for therapeutic benefit in patients with
cancer and chronic infections.
IDO-competent plasmacytoid DCs in mice and
humans
IDO expression is tightly regulated and is induced in
some cell types by infection and inflammation. Inter-
feron (IFN) response elements in transcriptional promo-
ters of mammalian IDO genes (ISRE, GAS) confer
responsiveness to interferons. Though some non-hema-
topoietic cell types express IDO under inflammatory
conditions, IDO expression is restricted to myeloid cells
(macrophages, DCs) in hematopoietic cell lineages
[32-34]. This review focuses on IDO expression in DC
subsets because DCs are specialized to acquire, process
and present antigens to T cells, leading to T cell activa-
tion. In recent published studies, Mellor and colleagues
identified a specific subset of murine plasmacytoid DCs
(CD19
+ pDCs) in spleen that express IDO selectively in
response to inflammatory signals (mediated by IFN type
1, IFNa) induced by the synthetic reagents soluble
CTLA4 (CTLA4-Ig) and DNA oligonucleotides contain-
ing un-methylated CpG motifs (CpGs) that ligate B7
(CD80/86) surface receptors, and intra-cellular Toll-
Like Receptor-9 (TLR9), respectively [35-38]. These
r e s p o n s e sw e r eh i g h l ys p e c i f i cf o rt h es m a l lc o h o r to f
splenic CD19
+ pDCs, which rapidly produced IFNa
after B7 and TLR9 ligation. IFNa was essential to
induce IDO in CD19
+ pDCs via an auto/paracrine
mechanism. Though CD19
+ pDCs are few in number
(~10% of total splenic DCs) their IDO-dependent sup-
pressive functions were dominant over the stimulatory
functions of all other DC subsets, as shown by the fact
that unfractionated DCs from B7 and TLR9 ligand trea-
ted mice exhibited potent T cell suppressive functions
ex vivo.
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IDO
+ pDC subsets in humans [39] and in tumor-drain-
ing LNs (TDLNs) in mice bearing melanomas [29,40].
In each case, IDO
+ pDCs exhibited potent T cell sup-
pressive functions when cultured with T cells ex vivo.
Collectively, these studies revealed that IDO expression
was inducible in specific subsets of human and murine
pDCs, and that the consequences of inducing IDO were
that DCs acquired potent T cell suppressive functions.
Infectious pathogens and IDO
Infectious pathogens provoke tissue inflammation, which
causes some host cells (such as macrophages and NK
cells) to release IFNs that induce IDO in some cells
[41]. Previously, it was assumed that IDO induced by
infections was a innate host defense mechanism that
functioned by starving infected cells, and perhaps cancer
cells, of tryptophan (an essential cell nutrient), which
limited the spread of infections [42]. However the dis-
covery that IDO has potent T cell regulatory effects
when expressed by DCs suggests that this mechanism
may be exploited to protect pathogens by suppressing
host T cell mediated immunity directed at pathogens
and infected cells. This notion provides the rationale
and the need for future studies on the role of indolea-
mine 2, 3 dioxygenase in regulating host immunity to
Leishmania infection. Studies on tumor-bearing mice
provide additional support for the notion that the IDO
mechanism is exploited by tumors to suppress anti-
tumor immunity. In tumor-bearing mice abnormally
high numbers of IDO
+ pDCs with potent T cell sup-
pressive functions accumulated in tumor-draining LNs
[29]. Thus, we hypothesize that pathogens, like tumors,
may exploit the IDO mechanism to evade effective host
T cell immunity potentially capable of completely elimi-
nating chronic infections. If this hypothesis is verified,
IDO-mediated suppression of pathogen-specific T cell
immunity may be targeted therapeutically using IDO
inhibitors to enhance effective T cell responses to
pathogen infections. Importantly, IDO inhibitors are
cheap to produce (e.g. D-1MT is an orphan drug) and
should be relatively easy to administer to patients living
in developing countries, two criteria emphasized by the
Bill and Melinda Gates Foundation in promoting
research on new approaches to treat chronic infections.
Hence, testing the hypothesis above will be an important
step in determining whether to proceed further with
developing IDO inhibitors for potential therapeutic use
in patients suffering from chronic infections.
Leishmania major infection in mice: a model for
chronic infection
In our recent studies [22], we observed IDO
+ cells in
lymph nodes (LNs) draining sites of L. major infection
in mice. We hypothesized that IDO
+ cells present in
draining LNs create local suppressive microenviron-
ments that facilitate L. major persistence by inhibiting T
cell immunity to pathogen antigens. We selected the L.
major infection in mice as the model system to test the
hypothesis posed above for several reasons. First, the L.
major infection model has been studied extensively by
immunologists and was the original source of the TH1/
TH2 ‘helper’ Tc e l lp a r a d i g mt h a tp r o v i d e dk e yi n s i g h t s
into alternative immune outcomes. Hence, L. major
infection of B6 and BALB/c mouse strains drives predo-
minantly TH1a n dT H2 responses, respectively. TH1
responses are more effective in controlling L. major
infections, but parasites are not eliminated completely
by B6 or BALB/c hosts. Thus, unlike pathogens that
cause acute infections (e.g. influenza virus), which are
eventually eliminated, L. major parasites always persist
in immune-competent hosts. Second, mechanisms that
explain L. major persistence have not been defined,
despite decades of research. Recently, Suffia et al., Belk-
aid et al, and Bertholet et al., reported the surprising




cells (Tregs) present at L. major infection sites in mice
proliferated specifically in response to L. major infected
DCs, were restricted to sites of infection, and that the
survival of Tregs was strictly dependent on parasite per-
sistence [43-45]. These findings suggested that host
Tregs, which maintain self-tolerance, are subverted by L.
major parasites to suppress host T cell immunity to
parasite antigens. Third, Leishmaniasis threatens about
350 million men, women and children in 88 countries
around the world. As many as 12 million people are
believed to be currently infected by leishmaniasis, with
about 1-2 million estimated new cases occurring every
year worldwide [46,47]. Finally, drug regimens used
against leishmaniasis (amphotericin B, pentamidine and
pentostam) have limited efficacies and pose severe toxi-
city issues. Hence, there is an urgent need to develop
less toxic and more efficacious drugs to target these
chronic infectious pathogens.
This review cannot over emphasize the need to con-
duct studies to test the hypothesis that L. major infec-
tion in B6 mice induces IDO-competent pDCs to
accumulate in LNs draining infection sites, which pre-
vent effector T cell activation and activate resting, but
functionally quiescent Tregs to acquire suppressor func-
tions in this tissue microenvironment. The choice of B6
and BALB/c (DO11.10) mice for our recent study [22]
was based on the need to use defined T cells from OT1
and OT2 T cell receptor transgenic (TCR Tg) with spe-
cificity for ovalbumin (OVA), as a means to test this
hypothesis. A conceptual model of IDO-mediated acti-
vation and effector T cell suppression following L.
major infection is summarized in additional file 2. The
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and naïve T cells that drive suppressive and nonsuppres-
sive outcomes under IDO-sufficient (+) and IDO-defi-
cient (-) conditions in response to L. major infection.
Induced IDO activity in DCs triggers cell stress
responses, and blocks IL6 production by pDCs them-
selves, and by other cells (e.g. macrophages) capable of
producing IL6. Under conditions of IDO ablation the
same stimuli do not create suppression, and instead
DCs stimulate naïve T cells, and express IL6, which
converts Tregs to TH17 T cells or promotes TH17 dif-
ferentiation from naïve CD4+ T cells.
New data [48,49] show that evidence for TH17 pheno-
type is related to Treg conversion under conditions of
IDO ablation. The authors showed that IDO activates
Tregs and blocks their conversion into TH17-like T
cells supporting the hypothesis that IDO dominantly
controls the functional status of Tregs in response to
inflammatory stimuli in physiological setting. Links
between L. major and activation of regulatory T cells
have been described though molecular mechanisms that
explain these links have not been described. Induced
IDO expression is strongly linked to activation of Tregs
in response to tumor growth and TLR9 ligand treatment
in mice, forming the basis of the guiding hypothesis we
put forward. The hypothesis that IDO inhibits natural
(T cell mediated) immunity is novel, though not univer-
sally accepted. The related notion that IDO contributes
to L. major persistence represents a novel paradigm.
However, even the notion that tumors or infectious
pathogens exploit the natural immunoregulatory IDO
mechanism to suppress T cell immunity does not yet
enjoy universal acceptance in the field of immunology.
It would be interesting to perform studies to test this
hypothesis, by assessing the effects of IDO-regulated
IL17 production on Tregs and TH17 T cells, using the
Treg specific marker, Foxp3. The use of Foxp3GFPKO
mice that express a Foxp3-GFP fusion protein [50] may
likely clear this controversy. This hypothesis can be
addressed further by determining the activation status of
Tregs using MLRs and cytokine profile analysis in the
infected relevant mice treated with oral D-1MT as well
as IDO1-KO mice.
Innovative Immunotherapy: Destruction of local
Immune privilege
The global diseases tuberculosis, AIDS, malaria and
leishmaniasis are caused by chronic pathogenic infec-
tions that are not cleared by natural immunity. Typically
treatments slow disease progression rather than indu-
cing pathogen clearance. Attempts to develop effective
therapeutic vaccines to clear chronic infections have
consistently failed. Even the search for effective prophy-
lactic vaccines is frustrating, as evidenced by the recent
failure of Merck’s Step vaccine to prevent new HIV
infections in ‘at risk’ individuals [51-53]. New perspec-
tives leading to innovative treatments are urgently
needed to address the global problem of chronic infec-
tions. From an immunologic perspective pathogen per-
sistence in individuals with competent immune systems
contradicts the fundamental tenet of immunity to non-
self and tolerance to self, prompting the question; why
do pathogen (non-self) antigens fail to stimulate effec-
tive immunity that leads to pathogen clearance? The
answer to this question may lie in the fact that some
pathogens evolved the ability to create local immune
privilege where immunity to non-self antigens is actively
suppressed. This novel perspective explains why tradi-
tional vaccine approaches are ineffective, even when vac-
cines stimulate systemic immunity, and implies that
natural immune regulatory mechanisms protect patho-
gens and infected cells from host immunity at local sites
of infection. Most importantly this perspective suggests
that novel therapies that destroy immune privilege will
be effective methods to eliminate persistent pathogen
infections. Acquired immune privilege is defined as a set
of local mechanisms that suppress the mature lympho-
cyte responses to antigens encountered in peripheral tis-
sues [54]; for example, acute L. major infection elicits
local IL10 production [55,56] which limits collateral
damage during initial infection, but is also immunosup-
pressive and allows the pathogen to persist [57].
Various groups have been studying a specific immune
regulatory mechanism that involves expression of the
enzyme indoleamine 2,3 dioxygenase (IDO) by particular
cell types such as certain subsets of dendritic cells (DCs)
[58-63]. IDO is induced by inflammation and by patho-
gens that cause all the infectious diseases mentioned
above. We hypothesize that local IDO expression creates
immune privilege at local sites of persistent infection.
The specific goal of the future studies should be to test
the prediction that IDO blockade coupled with che-
motherapy/vaccine therapy to destroy established
immune privilege, and block its re-establishment will
lead to pathogen clearance. The rationale for this inno-
vative approach is based on evidence that IDO inhibitors
and certain chemotherapeutic agents synergize to drive
more effective immune-mediated tumor clearance in
mice [64-66]; indeed Phase I clinical trials in cancer
patients to test the efficacy of the IDO inhibitor 1-
methyl-[D]-tryptophan (D-1MT) as a vaccine adjuvant
are underway at two US medical centers. In recent stu-
dies [22] we discovered that cutaneous L. major infec-
tion in mice induced DCs in lymph nodes draining
infected skin to express IDO, just as in lymph nodes
draining sites of melanoma growth [66]. These findings
suggest that L. major infection creates immune privilege
by inducing DCs in local inflamed lymph nodes to
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should be targeted to treating L. major infected B6 and
BALB/c mice with D-1MT and autoclaved leishmania
vaccine (ALM), and monitor the potential therapeutic
effects of combined immuno-chemotherapy on reducing
parasite loads and affecting parasite clearance. The
speedy execution and completion of studies targeted on
therapeutic potential and or immunochemotherapy will
provide critical mechanistic insights into the role of
IDO-expressing cells in creating immune privilege that
blocks host anti-parasite immunity.
Limitations of IDO and Leishmania Research
Overall, mechanisms that explain L. major persistence
have not been defined, despite decades of research. No
effective vaccine is yet available against this parasite and
its control relies primarily on chemotherapy. Since the
discovery of the pentavalent antimonials, (the first drug
for leishmaniasis treatment), [67], hitherto, the search
for lead molecules with anti-leishmanial activity, without
toxic effects, and able to overcome the emergence of
drug resistant strains, still remains viable limitation.
Poor health care and a deficiency of effective treatments
and cures means that Leishmania will remain a scourge
on humans unless a better understanding of why the
immune system tolerates such infections emerges from
research. Clearly, the identification and an in-depth
understanding of the type(s) of cells in which the para-
sites persist, and the elucidation of the mechanisms that
are essential for maintaining a stable host-parasite rela-
tionship, will be major tasks for the future. Although
parasite persistence always bears the risk of later reacti-
vation and reappearance of the disease, it remains
uncertain to date whether sterile immunity would be
advantageous to the host because parasite elimination
might also blunt T-cell memory and thereby enable
reinfection of the host. However, even without the goal
to find new strategies for the killing of hidden parasites
in vivo, studies on the mechanisms of parasite evasion
will certainly enrich our understanding of the anti-para-
site immune defense.
Conclusions
As summarized above, various study groups have identi-
fied a small subset of splenic IDO- competent pDCs
that are capable of influencing immune outcomes
greatly by expressing IDO and acquiring potent T cell
suppressive functions with a capacity to block the stimu-
latory properties of T cells [22,66]. These findings
showed that IDO induced by L. major infection attenu-
ated innate and adaptive immune responses. Thus, IDO
may act as a molecular switch regulating host responses,
and IDO inhibitor drugs are a potential new approach
to enhance host immunity to established leishmania
infections.
The main goal of future research should be to gener-
ate new knowledge to exploit the IDO mechanism for
optimal therapeutic gain in patients with leishmaniasis
and other similar infectious pathogens. Immunocompe-
tent humans eventually heal L. major lesions, inducing a
life-long powerful immunity. The only efficacious vac-
cine against leishmaniasis is Leishmanization, the pro-
cess of inoculating individuals with live parasites. It is
thought and felt that maintenance of immunity to Leish-
mania infection requires the presence of a chronic infec-
tion. Before IDO inhibitors are utilized to treat
leishmaniasis. It will be necessary to determine how
suppression of IDO will influence parasite persistence
and the induction of protective immunity. Indeed, to
this end studies must be carried out to investigate the
effects of inducing and ablating IDO in mice during
immunization against leishmaniasis. It is felt that such
investigative research will generate critical new knowl-
edge pertaining to the IDO mechanism and how to
exploit it to suppress T cell mediated immunity.
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effector T cell suppression following L. major infection. The model
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